<DOC>
	<DOCNO>NCT02223000</DOCNO>
	<brief_summary>Comparative pharmacokinetics 2-4 experimental modify release formulation oral solution BIBV 308 SE follow multiple dos , tolerability</brief_summary>
	<brief_title>Relative Bioavailability Tolerability Various Experimental Formulations BIBV 308 SE Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects previously enter least one BIBV 308 SE study ensure know subject absorb BIBV 308 SE Healthy subject determine result screen Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Age &gt; = 18 &lt; = 55 year Broca &gt; = 20 % &lt; = +20 % Poor individual absorption kinetics BIBV 308 SE previous study Any finding medical examination ( include blood pressure , pulse rate Electrocardiogram ( ECG ) ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder Chronic relevant acute infection Hypersensitivity BIBV 308 SE excipients Intake drug long halflife ( &gt; 24 hour ) &lt; = 1 month prior administration trial Use drug might influence result trial &lt; = 10 day prior administration trial Participation another trial investigational drug &lt; = 2 month day prior administration trial Smoker ( &gt; = 10 cigarette &gt; = 3 cigar &gt; = 3 pipes/day ) Inability refrain smoke study day Known alcohol drug abuse Blood donation &lt; = 1 month prior administration Excessive physical activity &lt; = 5 day prior administration History hemorrhagic diathesis History gastrointestinal ulcer , perforation bleed History bronchial asthma Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>